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Background: Recent studies implicate adipokines in the pathogenesis of inflammatory diseases, including psoriasis.
In this study we evaluated the significance of serum resistin levels in psoriasis patients using a meta-analysis
approach.223
Methods: Relevant articles were retrieved by searching the following English and Chinese databases: Cochrane
Library, PubMed, Springer Link, Chinese Biomedical Database (CBM) and Chinese National Knowledge Infrastructure
(CNKI). The retrieved studies were subjected to a thorough screening procedure to identify case–control studies
that contained the required data. Data was extracted from each study and Version 12.0 STATA statistical software
was employed for statistical analyses.
Results: Nine case–control studies, containing 421 psoriasis patients and 348 healthy controls, were included in this
study. The major result of the meta-analysis revealed a statistically significant association between serum resistin
levels and psoriasis (SMD = 2.22, 95%CI: 1.14-3.29, P < 0.001). Subgroup analysis based on ethnicity showed that,
compared to the healthy controls, serum resistin levels were markedly higher in psoriasis patients in both Asian and
Caucasian populations (Asians: SMD = 3.27, 95%CI = 1.62 ~ 4.91, P < 0.001; Caucasians: SMD = 0.91, 95%CI = 0.28 ~
1.54, P < 0.001).
Conclusions: Based on our results, we conclude that serum resistin level in psoriasis patients is higher than healthy
controls, and raises the possibility that elevated serum resistin levels may be a novel diagnostic marker in psoriasis
and may predict the occurrence of co-morbidities in psoriasis patients.
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Psoriasis is one of the most common chronic inflamma-
tory skin diseases characterized by infiltration of T cells
and hyper-proliferative keratinocytes [1,2]. Psoriasis af-
fects 2-3% of population worldwide, with equal gender
distribution, and can lead to substantial morbidity and
mortality directly from the disease as well as from the
effect of co-morbodities [1,3]. Psoriasis has a major
negative impact on quality of life in patients and consid-
erable psychosocial disability is associated with the dis-
ease, along with the high costs of treatment [4]. Psoriasis
can emerge at any time in life but it usually peaks be-
tween the ages of 30–39 and 60–69 and is associated
with co-morbidities such as cardiovascular diseases,* Correspondence: huanghuiyun0416@163.com
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unless otherwise stated.psoriatic arthritis and depression [2,5]. The prevalence
rate of psoriasis around the world depends on the geo-
graphical region and ethnicity. Japan has the lowest inci-
dence of psoriasis (0.2%), while Faroe Islands has the
highest incidence (2.8%) [2,4]. Psoriasis affects both skin
and the joints, ranging in severity from a few scattered
red, scaly plaques to the involvement of the entire body
surface [4,6]. Psoriasis patients often need life-long treat-
ment and medical support, and the condition may pro-
gressively worsen with age or fluctuate in severity,
depending on genetic and environmental factors [4,7].
Psoriasis patients are especially prone to premature ath-
erosclerosis and increased risk of cardiovascular events
[2]. The pathogenesis of psoriasis is only partly under-
stood and involves genetic, environmental and immuno-
logical factors, with other contributing factors such as
smoking, stress, trauma, and alcohol consumption [4,7].This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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with increased serum C-reactive protein, leptin and
resistin levels [5]. Recent study shows that resistin plays
a predominant role in the pathogenesis of psoriasis, par-
ticularly in obese patients [8].
Resistin is a 12.5 kDa polypeptide that belongs to the
inflammatory zone protein family [9,10]. Resistin is a
cysteine rich protein primarily produced by peripheral
blood mononuclear cells in humans and by white adi-
pose tissues in rodents [11]. Previous studies showed
that resistin regulates insulin sensitivity and glucose me-
tabolism, and is a mediator between diabetes and obes-
ity, exhibiting a positive correlation with body mass
index [12,13]. Importantly, resistin induces the secretion
of pro-inflammatory cytokines, such as interleukin-6
(IL-6), IL-12 and tumor necrosis factor α (TNF-α)
[9,14]. Accordingly, elevated serum resistin level is de-
tected in obesity and in a variety of malignancies such as
colorectal cancer, breast cancer, non-small cell lung can-
cer and prostate cancer [15-17]. Interestingly, high
serum resistin levels are also observed in psoriasis pa-
tients [18]. Therefore, it is possible that, in addition to
the involvement of resistin in metabolic syndrome, resis-
tin mediated increase in secretion of pro-inflammatory
cytokines such as IL-6, IL-12 and TNF-α, through acti-
vation of nuclear factor-B signal pathway, may also dir-
ectly effect the pathogenesis of psoriasis [19,20].
Consistent with this view, serum levels of resistin are
positively associated with psoriasis severity, with higher
serum resistin levels found in more advanced stages of
psoriasis [21,22]. Therefore, resistin level may be useful
as a biomarker for diagnosis of psoriasis and to adjust
the treatment regimen during fluctuating severity of the
disease [21]. Accordingly, multiple studies proposed that
serum level of resistin may be effective for predicting the
presence of psoriasis [18,23], but other studies showed
contradictory results [24,25]. Therefore, in the present
meta-analysis, we evaluated the relationship between
serum resistin levels and psoriasis in order to test the
feasibility of using serum resistin levels as diagnostic and
prognostic tool for psoriasis.
Materials and methods
Search strategy
Published case–control studies were identified via com-
prehensive search (last search April 30st, 2014) of
Cochrane Library, PubMed, Springer Link, Chinese Bio-
medical Database (CBM) and Chinese National Know-
ledge Infrastructure (CNKI) databases. The studies
reporting the association between serum Resistin levels
and psoriasis were identified from the databases by util-
izing the search terms (“Resistin”), and (“Psoriasis” or
“psoriasis” or “Psoriasis Vulgaris” or “Psoriasis arthro-
pathica” or “Pustular psoriasis” or “Pustulosis Palmariset Plantaris” or “Palmoplantaris Pustulosis” or “Pustular
Psoriasis of Palms and Soles”). Additionally, manual
searches were employed to identify potentially relevant
articles from cross-references of important studies.
Study selection
Randomized intervention case–control studies investi-
gating the association between serum resistin levels and
psoriasis were considered for this meta-analysis. The
diagnosis of the enrolled psoriasis patients was based on
the characteristic signs and symptoms and was con-
firmed by histopathological examination [26]. Studies
with insufficient information on serum resistin levels
were excluded. The included studies contained more
than 50 cases per study and studies with less than 50
psoriasis cases were excluded. Duplicate studies or stud-
ies lacking complete or unavailable data were also a
cause for exclusion. If the same sample was used in pre-
vious studies, only the most complete or the most recent
study was enrolled.
Data extraction
To minimize bias and improve the reliability, two inves-
tigators independently collected information based on
the selection criteria and reached a consensus on all
items after through discussion and reexamination. The
following relevant data were extracted from the eligible
studies: surname of first author, year of publication,
source of publication, study type, study design, source of
publication, sample size, age, gender/sex, ethnicity and
country of origin, study type, detection method of serum
resistin serum levels, and resistin expression levels. Data
was separately extracted and grouped into Asians and
Caucasians based on ethnicity. All the authors agreed
with the final enrolled studies.
Quality assessment
The methodological quality of the enrolled studies was
measured by critical appraisal skill program (CASP) cri-
teria by two investigators (http://www.casp-uk.net/). The
following criteria were used: the study focuses on a
clearly focused issue (CASP01); the research problem is
acceptable and the research design resolve the study
problem (CASP02); the cases selected in an appropriate
way (CASP03); the controls recruited in an appropriate
way (CASP04); the evaluation for exposure factors is
precise to minimize bias (CASP05); the study controls
other important confounding factors (CASP06); the
study result is complete (CASP07); the study result is ac-
curate (CASP08); the study result is reliable (CASP09);
the study result can be applied to the local population
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Figure 1 Flow chart of literature search and study selection.
Table 1 Characteristics of included studies focused on protein expression of resistin
First author Year Ethnicity Number
Sample size Gender (M/F) Age (years)
Method
Case Control Case Control Case Control
Rajappa M [31] 2014 Asians Large 60 60 50/10 49/11 41.97 ± 13.40 43.75 ± 11.14 ELISA
Takahashi H [21] 2013 Asians Large 62 58 41/21 40/18 44.2 (27~74) 39.5 (29~69) ELISA
Romani J [24] 2013 Caucasians Large 50 50 31/19 31/19 46.37 ± 17.29 46.06 ± 17.53 ELISA
Lora V [18] 2013 Caucasians Small 27 27 15/12 15/12 49.9 ± 12.3 48.1 ± 8.2 ELISA
Ozdemir M [25] 2012 Asians Small 26 26 14/12 13/13 42.4 ± 13.2 40.6 ± 10.2 ELISA
Nakajima H [23] 2011 Asians Small 30 30 - - - - ELISA
Lan CX [30] 2010 Asians Large 70 30 42/28 18/12 38.31 ± 3.34 37.63 ± 3.29 ELISA
Coimbra S [33] 2010 Caucasians Large 66 37 35/31 16/21 - - ELISA
Johnston A [32] 2008 Caucasians Small 30 30 16/14 13/16 52.87 (24~77) 47.14 (22~83) ELISA
M, male; F, female; ELISA, enzyme linked immunosorbent assay; RIA, radioimmunoassay.
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Figure 2 Quality of enrolled studies using critical appraisal skill program (CASP).
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To provide quantitative evidence and minimize variance
of the summary, this meta-analysis was performed by
applying random-effect model or fixed-effect model.
When heterogeneity existed among studies, a random-
effect model was used; otherwise a fixed-effect model
was utilized. The pooled standardized mean difference
(SMD) with 95% confidence intervals (CI) was calculated














Z test (Z = 4.04, P < 0.001)
Figure 3 Forest plot of the differences in serum resistin levels between psby Z test. To investigate potential effect modification,
subgroup analyses based on ethnicity and sample size
were conducted. Moreover, Cochran’s Q-statistic (P < 0.05
was regarded as statistically significant) was applied to
evaluate the heterogeneity among the included trials [27].
I2 test evaluated the possibility of heterogeneity across
studies [28]. The sensitivity analysis was conducted by re-
moving any single study at a time to assess the reliability
























oriasis and healthy controls.
Figure 4 Subgroup analyses for the differences of serum resistin levels between psoriasis patients and healthy controls (A: Ethnicity; B: Number).
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The symmetry shape of the funnel plot was further
confirmed by the Egger's test [29]. A P value of < 0.05
was considered as statistically significant. All statis-
tical analyses were conducted with the usage of
STATA software, version 12.0 (Stata Corp, College
Station, TX, USA).Results
Characteristics of enrolled studies
The database search originally resulted in retrieval of 51
articles related to the search keywords. The flow diagram
of the study selection process is presented in Figure 1.
After screening the title and keywords, 26 articles were
removed, including 1 duplicate, 5 letters, reviews or
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Figure 5 Sensitivity analysis of the summary odds ratio coefficients on the differences of serum resistin levels between psoriasis patients and
healthy controls.
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the research topic. The remaining 25 studies were reexa-
mined and additional 16 studies were excluded, out of
which 2 was not case–control studies, 5 were not rele-
vant to resistin, 7 were not relevant to psoriasis and 2
contained insufficient data. Finally, 9 case–control stud-
ies [18,21,23-25,30-33], containing a combined total of
769 subjects (421 patients with psoriasis and 348 healthy
controls) were enrolled in this meta-analysis. The publi-
cation year of these studies ranged between 2008 and
2014. All articles were case–control studies reporting
the relationship between serum resistin levels and
psoriasis in Asian (5 studies) and Caucasian populations
(4 studies). The detection method in all 9 studies was
enzyme linked immunosorbent assay (ELISA). Table 1
displays the study characteristics and the methodological
quality of the enrolled studies is shown in Figure 2.
Resistin serum levels in psoriasis
A total of 9 studies reported serum resistin levels in
psoriasis patients. The major result of the correlation be-
tween resistin levels and psoriasis is shown in Figure 3.
The random-effect model was applied due to existence
of heterogeneity among the studies (P < 0.001). A posi-
tive association between resistin serum levels and psoria-
sis was identified in this meta-analysis (SMD = 2.22,
95%CI: 1.14-3.29, P < 0.001). Subgroup analysis based on
ethnicity revealed that serum resistin levels were signifi-
cantly higher in psoriasis patients, compared to healthy
controls, in both Asians and Caucasians (Asians: SMD =
3.27, 95%CI = 1.62 ~ 4.91, P < 0.001; Caucasians: SMD =
0.91, 95%CI = 0.28 ~ 1.54, P < 0.001) (Figure 4A). Further,
subgroup analysis by sample size indicated a statisticallysignificant association between resistin levels and psoria-
sis in both large sample size and small sample size sub-
groups (both P < 0.05) (Figure 4B).
Sensitivity analysis and publication bias
The removal of any single study in sensitivity analysis
did not change the overall statistical significance, sug-
gesting that this meta-analysis is relatively stable and
credible (Figure 5). Additionally, funnel plots of the
nine studies showed slight asymmetry and Egger's test
showed publication bias in our current meta-analysis
(P = 0.008) (Figure 6).
Discussion
In the present meta-analysis, we examined the relationship
between serum levels of resistin and psoriasis. The results
of our meta-analysis revealed that higher serum resistin
levels positively correlated with psoriasis disease progres-
sion, indicating that resistin might be a potential bio-
marker for diagnosis and prognosis in psoriasis patients.
The clinical features of psoriasis include epidermal hyper-
proliferation, impairment of keratinocyte differentiation,
increased angiogenesis and widespread immune distur-
bances. The dermal infiltrate in psoriasis contains various
immune cells and psoriasis is largely a T-helper (Th)17/
Th1-mediated autoimmune disease. More recently, a cyto-
kine sharing the p40 unit with IL-12 and IL-23 was
observed to be highly expressed in psoriatic skin. This
cytokine was crucial for generation of Th17 cells with a
pathogenic phenotype [19]. In humans, resistin is mainly
produced by monocytes and macrophages in adipose tis-
sue and its expression is stimulated by pro-inflammatory
agents such as TNF-α, IL-1β, IL-6 and lipopolysaccharide.
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Figure 6 Publication biases on the differences of serum resistin levels between psoriasis patients and healthy controls.
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in activated B cells, suggesting a pathogenic cycle that
sustains inflammatory cytokine production, along with
resistin secretion [10,34]. Induction of CXCL8 and TNF-α
by resistin in monocytes population in blood is also linked
with psoriasis pathophysiology [21,35] and TNF-α stimu-
lates keratinocyte proliferation and T cells recruitment to
the skin, thus a close relationship between resistin and
TNF-α-mediated inflammation exists in psoriasis [36,37].
In addition, resistin may play a role in Foxp3+ regulatory
T-cell (Treg) deficiency in psoriasis [38]. Foxp3+ regulatory
T-cells (Treg) are inhibitors of autoimmune responses.
By inducing and maintaining immunological tolerance,
Foxp3+ Treg cells inhibit infiltration of Foxp3+ lympho-
cytes into skin lesions in psoriasis patients [39]. Based
on the above analysis, we can conclude that serum
resistin level plays a pivotal role in the development of
psoriasis through inflammatory factors such as TNF-α
and decreased functioning of Foxp3+ Treg population.
In line with our result, Boehncke et al. observed a close
link between resistin and the PASI score, a measure for
psoriasis clinical severity, implicating inflammatory me-
diators such as TNF-α [40].
In order to consider other factors that may affect the
link between serum resistin level and psoriasis, we per-
formed a stratified analysis based on ethnicity. Subgroup
analysis showed that higher serum resistin levels were
observed in both Asians and Caucasian psoriasis pa-
tients, compared to their healthy counterparts, suggest-
ing no detectable racial differences in our analysis.
Although our meta-analysis was a practical way to
generate a powerful estimate of true effect-size, with lowrandom error compared to individual studies, several
potential limitations did exist. Firstly, our study could
not access all available sources that reported data related
to resistin and psoriasis due to language limitations.
Therefore, our study contains a relatively smaller sample
size. A second limitation inherent to all meta-analysis is
the possibility of publication bias, which results from
publication of studies with favorable results, which is
much easier than publication of unfavorable results.
Another potential limitation is heterogeneity, indicating
a lack of sensitivity in the pooled empirical studies. In
particular, this analysis was conducted on psoriasis pa-
tients differing in clinical severity and receiving various
treatments, all of which could have an influence on the
results. Despite the above limitations, this is the first
meta-analysis on the association between serum resistin
levels and psoriasis. More importantly, our meta-analysis
uses a statistical approach to combine the results from
multiple studies. We avoided publication bias by using
registries of trials that met our inclusion criteria. Further,
inconsistent results were rigorously quantified and ana-
lyzed in our meta-analysis, which led to more reliable
conclusions.
Taken together, the present study revealed higher serum
resistin levels in psoriasis patients compared to healthy
controls, indicating that elevated serum resistin levels
strongly correlate with psoriasis progression. Therefore,
serum resistin level could be a valuable biomarker in evalu-
ating the clinical status of psoriasis patients. Nevertheless,
due to the limitations in this study, it is necessary to extend
our analysis to a larger population to confirm the relation-
ship between serum resistin levels and psoriasis.
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